Drug intelligence / Profile preview

indium-111-labelled anti-CD66 monoclonal antibody

Development stage: Unknown
Lead developer: Telix Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Indium-111-labelled anti-CD66 monoclonal antibody is a radiolabelled diagnostic and dosimetry agent used as part of a radioimmunotherapy regimen for children with relapsed or refractory leukemia. The antibody component, BW250/183, is a murine IgG1 kappa monoclonal antibody that targets CD66 (carcinoembryonic antigen-related cell adhesion molecules), which are expressed on granulocytes and bone marrow cells. This agent is administered for SPECT imaging and dosimetry purposes to evaluate biodistribution and calculate the appropriate dose for a subsequent therapeutic administration of the yttrium-90-labelled version of the same antibody. It has been evaluated in Phase I trials at Great Ormond Street Hospital as part of a reduced-intensity conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.

Other names: [111In]-anti-CD66 monoclonal antibody111In-BW250/183indium-111-labelled BW250/183indium-111-labelled anti-CD66 antibodyindium111-labelled anti-CD66 antibodyindium 111-labelled anti-CD66 antibody

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on indium-111-labelled anti-CD66 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on indium-111-labelled anti-CD66 monoclonal antibody.

Explore the full profile